Cambridge, United States
BlueRock Therapeutics is a cutting-edge, clinical-stage cell therapy company dedicated to reshaping the landscape of disease treatment. Emphasizing the transformative potential of cell therapy, it has constructed a promising pipeline targeting severe neurological and ophthalmic conditions. Key clinical programs are pioneering novel therapies for Parkinson’s disease and primary photoreceptor diseases.
Founded in 2016, BlueRock Therapeutics was initially a joint venture involving Versant Ventures and Leaps by Bayer, becoming a wholly owned subsidiary of Bayer AG by late 2019. The company embodies values of resilience, mission-driven integrity, and a commitment to community.
In the rapidly evolving Biopharma sector, BlueRock Therapeutics stands out with a $1.00B acquisition investment by Bayer in August 2019, signifying strong backing and belief in its potential. With headquarters in the United States, it is uniquely poised to deliver groundbreaking cellular therapies.
